Adult Dosing
Acute bacterial skin and skin structure infection (ABSSS)
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
See Supplemental Patient Information
- Prescribing therapy in the absence of a proven suspected bacterial infection may increase the risk of the development of drug-resistant bacteria
- Alternative therapy should be considered in treating patients with neutropenia and acute bacterial skin and skin structure infection as the safety and efficacy of tedizolid have not been evaluated in patients with neutropenia
- Therapy can alter the normal flora of the colon and may cause overgrowth of C. difficile contributing to the development of mild to fatal Clostridium difficile-associated diarrhea (CDAD)
- C. difficile produces toxins A and B which contribute to CDAD. Hypertoxin producing strains causes increased morbidity and mortality since these infections can be refractory to antibiotic therapy and may require colectomy
- Consider CDAD in all the patients who present with diarrhea following antibiotic use
- If CDAD suspected or confirmed discontinue the therapy and provide appropriate fluid, electrolyte, and protein supplementation along with antibiotics for C. difficile and surgical evaluation as needed
Supplemental Patient Information
- Patients should be informed that therapy may be taken with or without food
- Patient should be informed to take missed dose as soon as possible anytime up to 8 hr prior to the next scheduled dose
- If < 8 hr remain before the next dose, wait until the next scheduled dose
Pregnancy Category:C
Breastfeeding: Tedizolid is excreted in rat milk, but it is unknown whether it is excreted in human milk. Manufacturer advises caution.
